V Kiran Vemuri Selected Research

AM4113

2/2013	Analysis of tolerance and behavioral/physical dependence during chronic CB1 agonist treatment: effects of CB1 agonists, antagonists, and noncannabinoid drugs.
1/2011	The neutral cannabinoid CB₁ receptor antagonist AM4113 regulates body weight through changes in energy intake in the rat.
3/2008	The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats.
12/2007	A neutral CB1 receptor antagonist reduces weight gain in rat.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

V Kiran Vemuri Research Topics

Disease

3	Obesity 01/2015 - 03/2008
2	Hyperalgesia 12/2018 - 09/2012
2	Neuralgia (Stump Neuralgia) 12/2018 - 09/2012
2	Weight Gain 01/2015 - 12/2007
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2015 - 03/2008
2	Hypothermia 08/2013 - 01/2013
2	Nausea 03/2013 - 03/2008
2	Vomiting 03/2013 - 12/2007
2	Body Weight (Weight, Body) 01/2011 - 12/2007
1	Chronic Pain 12/2018
1	Dyslipidemias (Dyslipidemia) 01/2015
1	Catalepsy 08/2013
1	Anhedonia 03/2013
1	Shock 02/2013
1	Peripheral Nervous System Diseases (PNS Diseases) 09/2012
1	Cold Hypersensitivity 09/2012
1	Fatty Liver 08/2010
1	Insulin Resistance 08/2010
1	Thrombosis (Thrombus) 03/2008
1	Overweight 03/2008
1	Immune System Diseases (Immune Disorders) 03/2008
1	Inflammation (Inflammations) 03/2008
1	Weight Loss (Weight Reduction) 12/2007
1	Atherosclerosis 01/2006
1	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2006
1	Asthma (Bronchial Asthma) 01/2006
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2006
1	Rheumatoid Arthritis 01/2006
1	Multiple Sclerosis 01/2006

Drug/Important Bio-Agent (IBA)

7	CannabinoidsIBA 01/2015 - 12/2007
6	CB1 Cannabinoid Receptor (CB1 Receptor)IBA 12/2018 - 12/2007
5	EndocannabinoidsIBA 01/2015 - 01/2006
4	AM4113IBA 02/2013 - 12/2007
3	9- (hydroxymethyl)- 3- (1- adamantyl)hexahydrocannabinolIBA 08/2013 - 01/2013
2	Cannabinoid Receptors (Cannabinoid Receptor)IBA 12/2018 - 03/2013
2	Paclitaxel (Taxol)FDA LinkGeneric 12/2018 - 09/2012
2	Opioid Analgesics (Opioids)IBA 12/2018 - 02/2013
2	Morphine (MS Contin)FDA LinkGeneric 12/2018 - 02/2013
2	AM 251 (AM251)IBA 01/2015 - 12/2007
2	RimonabantIBA 03/2013 - 02/2013
2	Mesylates (Mesylate)IBA 02/2013 - 01/2013
1	cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester (URB597)IBA 12/2018
1	fatty-acid amide hydrolase (fatty acid amide hydrolase)IBA 12/2018
1	diphenyl (biphenyl)IBA 12/2018
1	URB937IBA 12/2018
1	Therapeutic UsesIBA 12/2018
1	LeptinIBA 01/2015
1	CorticosteroneIBA 01/2015
1	Insulin (Novolin)FDA Link 01/2015
1	GlucocorticoidsIBA 01/2015
1	SCH 23390IBA 02/2013
1	Haloperidol (Haldol)FDA LinkGeneric 02/2013
1	pyrazoleIBA 02/2013
1	quinolineIBA 02/2013
1	Dopamine (Intropin)FDA LinkGeneric 02/2013
1	Methamphetamine (Desoxyn)FDA LinkGeneric 02/2013
1	methanandamideIBA 02/2013
1	Naltrexone (ReVia)FDA LinkGeneric 02/2013
1	(3R)- ((2,3- dihydro- 5- methyl- 3- ((4- morpholinyl)methyl)pyrrolo- (1,2,3- de)- 1,4- benzoxazin- 6- yl)(1- naphthalenyl))methanone (WIN 55,212)IBA 01/2013
1	3- (1- hexylcyclobut- 1- yl)- 6a,7,8,9,10,10a- hexahydro- 6,6- dimethyl- 6H- dibenzo(b,d)pyran- 1,9 diolIBA 01/2013
1	Cisplatin (Platino)FDA LinkGeneric 09/2012
1	3- (1,1- dimethyl- heptyl)- 1- hydroxy- 9- methoxy- benzo(c)chromen- 6- oneIBA 09/2012
1	plerixafor FDA Link 09/2012
1	Glucose (Dextrose)FDA LinkGeneric 08/2010
1	LipidsIBA 08/2010
1	LigandsIBA 03/2008
1	Pharmaceutical PreparationsIBA 03/2008
1	EmeticsIBA 12/2007
1	Appetite Depressants (Anorectics)IBA 12/2007

Therapy/Procedure

2	Therapeutics 12/2018 - 03/2008
2	Analgesia 08/2013 - 01/2013
2	Drug Therapy (Chemotherapy) 09/2012 - 03/2008
1	Oral Administration 01/2011